Elan has sold the rights of Abelcet, its treatment for fungal infections, to Enzon for $370 million. The deal is Elan's first major disposal as part of its stated plan to raise $1.5 billion ...

Home » Elan's Abelcet, Sales Force Go To Enzon For $370M. X. Upgrade your daily dose of biopharma and medtech news. Subscribe to BioWorld™ news services. See subscription options. To read the full ...

Enzon Inc. signed an agreement with troubled Irish pharmaceutical company Elan Corp. plc to buy the North American and Japanese rights to Abelcet, Elan's drug for severe fungal infections, for $370 ...

Elan , the crisis-ridden Irish pharmaceuticals company, has sold its antifungal drug Abelcet to its US rival Enzon for $370m in cash. Garo Armen, Elan's new chief executive, said the sale was an ...

Elan's shareholders have approved the sale of its US, Canadian and any Japanese rights to Abelcet, its injectible antifungal agent, to Nasdaq-quoted Enzon at an extraordinary general meeting today.